Efficacy and Safety of Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy (HbA1c 7.0-9.5%)
Public ClinicalTrials.gov record NCT00728351. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Double-blind, Randomized Study to Compare the Efficacy of 24 Weeks Treatment With Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) Versus Metformin Monotherapy (1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy.
Study identification
- NCT ID
- NCT00728351
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 317 participants
Conditions and interventions
Conditions
Interventions
- vildagliptin + metformin Drug
- metformin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 78 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2008
- Primary completion
- Jan 31, 2010
- Completion
- Not listed
- Last update posted
- Dec 18, 2020
Started 2008
United States locations
- U.S. sites
- 16
- U.S. states
- 13
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Pine Bluff | Arkansas | 71603 | — |
| Not listed | Long Beach | California | 90806 | — |
| Not listed | Denver | Colorado | 80209 | — |
| Not listed | Bangor | Maine | 04401 | — |
| Not listed | Billings | Montana | 59102 | — |
| Novartis Investigative Site | New Brunswick | New Jersey | 08903 | — |
| Not listed | Trenton | New Jersey | 08611 | — |
| Not listed | Wilmington | North Carolina | 28409 | — |
| Not listed | Oklahoma City | Oklahoma | 73104 | — |
| Not listed | Uniontown | Pennsylvania | — | — |
| Not listed | Taylors | South Carolina | 29687 | — |
| Not listed | Houston | Texas | 77023 | — |
| Not listed | Houston | Texas | 77074 | — |
| Not listed | Houston | Texas | 77081 | — |
| Not listed | Norfolk | Virginia | 23510 | — |
| Not listed | Wenatchee | Washington | 98801 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 47 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00728351, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 18, 2020 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00728351 live on ClinicalTrials.gov.